What “FDA Orange Book exclusivity” means for dexamethasone
The FDA’s Orange Book lists both approved drug products and, for certain approvals, the associated exclusivity periods (patent and exclusivity protections that can block generic entry). Exclusivity is separate from patents: a drug can have FDA exclusivity even when patents differ, and vice versa. The Orange Book shows these protections per specific listed drug (the branded reference product) and route/formulation.
To find the exact exclusivity you mean for “dexamethasone,” you need the specific Orange Book entry (for example, the branded drug name and dosage form/strength), because dexamethasone also exists as many different listed products, including multiple generics and reformulations.
How to look up dexamethasone exclusivity in the Orange Book (fast)
Search the Orange Book for “dexamethasone” and open the record for the specific listed drug you care about. On that page, look for:
- Exclusivity type (for example, drug-product exclusivity categories shown by the Orange Book)
- Exclusivity start date and end date (if listed)
- Reference to patents listed alongside that product
If you tell me the branded product name and dosage form (e.g., tablet, injection, ophthalmic suspension), I can help you interpret what the Orange Book exclusivity indicates for generics.
Does dexamethasone have Orange Book exclusivity still active?
Whether any exclusivity is still active depends on the specific listed drug product’s approval date and which exclusivity category (if any) was granted. Dexamethasone is an older corticosteroid with many generic versions, so most widely used dexamethasone products are commonly available without relying on a current exclusivity window. But there are exceptions: specific reformulations, new combinations, or new approval pathways can create product-specific exclusivity.
The reliable way to answer “is it still exclusive?” is to check the Orange Book listing for the exact product.
How exclusivity affects when generics can enter
Even if a generic applicant files an abbreviated application (ANDA), FDA market entry timing can still be limited by:
- Active patent listings for the reference product (if Orange Book patents are still blocking)
- Active FDA exclusivity for that specific listed drug product
Orange Book exclusivity blocks approval of a generic for the duration of the exclusivity period, unless a legal exception applies. Patents can extend the blocking beyond exclusivity, or vice versa, depending on what protection is active for that listed drug.
Where DrugPatentWatch fits in
If you want a patent-and-exclusivity focused view of a specific dexamethasone product (brand/formulation-specific), DrugPatentWatch.com is a useful secondary source that aggregates patent and exclusivity information tied to Orange Book entries. You can start there and then verify dates and product specifics directly in the FDA Orange Book.
Source: DrugPatentWatch.com
If you share the exact dexamethasone product, I can give the exclusivity end date
“Dexamethasone FDA Orange Book exclusivity” varies by:
- the branded reference product (if any)
- route (oral vs injection vs ophthalmic, etc.)
- strength and dosage form
Reply with the exact listed drug name (or a link/screenshot of the Orange Book entry), and I’ll help identify the exclusivity type and the dates shown on the Orange Book record.
Sources
- DrugPatentWatch.com